Dosimetry-Guided 177Lu-DOTATATE Treatment Planning Using 64Cu-DOTATATE As a Surrogate
Latest Information Update: 21 May 2025
At a glance
- Drugs Copper 64 DOTATATE (Primary) ; Lutetium-(177Lu)-oxodotreotide (Primary)
- Indications Neuroendocrine tumours
- Focus Therapeutic Use
Most Recent Events
- 04 Mar 2025 Planned End Date changed from 1 Apr 2025 to 1 Feb 2026.
- 04 Mar 2025 Planned primary completion date changed from 1 Apr 2025 to 1 Feb 2026.
- 04 Mar 2025 Planned initiation date changed from 1 Feb 2025 to 1 Mar 2025.